Literature DB >> 7543907

Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome.

N Yuki1, Y Ichihashi, T Taki.   

Abstract

Sera of patients who develop Guillain-Barré syndrome (GBS) subsequent to Campylobacter jejuni enteritis frequently have IgG anti-GM1 antibody. Lipopolysaccharide (LPS) of C. jejuni isolated from a GBS patient has a GM1 ganglioside-like structure. IgG subclass distribution of the anti-GM1 antibody in GBS patients is mainly restricted to IgG1 and IgG3. Since IgG antibodies to bacterial polysaccharide generally are restricted to IgG2 subclass, some investigators have assumed that either the general rules for immune response to LPS are broken in the patients or an alternative antigen has yet to be identified. To clarify whether the LPS participates in the production of the anti-GM1 antibody, we investigated the subclass of IgG antibody to the LPS that bears GM1-like structure. The subclasses of IgG antibody to the LPS were restricted predominantly to IgG1 and IgG3. The GM1 epitope-bearing LPS may function in the production of the anti-GM1 antibody in patients with GBS subsequent to C. jejuni infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543907     DOI: 10.1016/0165-5728(95)00052-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

3.  Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome.

Authors:  A Neisser; H Bernheimer; T Berger; A P Moran; B Schwerer
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 4.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Human antibody response to Helicobacter pylori lipopolysaccharide: presence of an immunodominant epitope in the polysaccharide chain of lipopolysaccharide.

Authors:  S i Yokota; K i Amano; S Hayashi; T Kubota; N Fujii; T Yokochi
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.

Authors:  C W Ang; M A De Klerk; H P Endtz; B C Jacobs; J D Laman; F G van der Meché; P A van Doorn
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

7.  Anti-GQ1b IgG antibody syndrome: clinical and immunological range.

Authors:  M Odaka; N Yuki; K Hirata
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

Review 8.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

9.  Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.

Authors:  Amjad A Ilyas; Zi-Wei Chen
Journal:  J Neuroimmunol       Date:  2007-06-07       Impact factor: 3.478

10.  The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion.

Authors:  Rogier Louwen; Astrid Heikema; Alex van Belkum; Alewijn Ott; Michel Gilbert; Wim Ang; Hubert P Endtz; Mathijs P Bergman; Edward E Nieuwenhuis
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.